Send to

Choose Destination
Geburtshilfe Frauenheilkd. 2013 Sep;73(9):932-940.

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.

Author information

Department of Pathology, University of Heidelberg, Heidelberg.
Stratifyer Molecular Pathology GmbH, Köln.
Department of Gynaecology and Obstetrics, University of Heidelberg, Heidelberg.
Institute of Surgical Pathology, University Hospital Zürich, Zürich, Switzerland.
Dept. of Pathology, University Medical Canter Hamburg-Eppendorf, Hamburg.
Institute of Pathology, Medizinische Hochschule Hannover, Hannover.
National Center of Tumor Diseases, Heidelberg.


in English, German

Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.


breast cancer; multigene assays; prognosis

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York Icon for PubMed Central
Loading ...
Support Center